Homobutein

Homobutein

SCHEMBL633522

COc1cc(C=CC(=O)c2ccc(O)cc2O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
NFKB1 P19838 4/20 1.00
TDP1 Q9NUW8 3/20 1.00
NFKB2 Q00653 3/20 1.00
RELA Q04206 3/20 1.00
ABCG2 Q9UNQ0 4/20 0.85
CYP3A4 P08684 4/20 0.85
TP53 P04637 3/20 0.85
MAPT P10636 3/20 0.85
HPGD P15428 3/20 0.85
ALOX15 P16050 3/20 0.85
MAPK1 P28482 3/20 0.85
ALDH1A1 P00352 2/20 0.85
ALOX12 P18054 1/20 0.85
SMN1; SMN2 Q16637 1/20 0.85
CHRNA7 P36544 2/20 0.82
CTSL P07711 1/20 0.75
PTGS1 P23219 1/20 0.74
PTGS2 P35354 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Homobutein SCHEMBL31028350 1.00 MEN1 (1.00) MEN1KMT2ANFKB1TDP1NFKB2
Homobutein SCHEMBL25190880 1.00 MEN1 (1.00) MEN1KMT2ANFKB1TDP1NFKB2
Homobutein SCHEMBL633521 1.00 MEN1 (1.00) MEN1KMT2ANFKB1TDP1NFKB2
Homobutein SCHEMBL8154420 0.96 MEN1 (0.93) MEN1KMT2ANFKB1TDP1NFKB2
SCHEMBL633469 0.92 ABCG2 (1.00) MEN1KMT2ANFKB1TDP1NFKB2
SCHEMBL30383806 0.92 ABCG2 (1.00) MEN1KMT2ANFKB1TDP1NFKB2
SCHEMBL633470 0.92 ABCG2 (1.00) MEN1KMT2ANFKB1TDP1NFKB2
SCHEMBL25217986 0.92 ABCG2 (1.00) MEN1KMT2ANFKB1TDP1NFKB2
SCHEMBL25219851 0.92 MAOB (0.85) MEN1KMT2ANFKB1TDP1NFKB2
SCHEMBL25195985 0.92 MAOB (0.85) MEN1KMT2ANFKB1TDP1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230099567-A1 COMPOSITION FOR TREATMENT, PREVENTION, OR AMELIORATION OF LYMPHEDEMA RAPPELER CO., LTD. (KR) 2023-03-30 US claimed
US-9877946-B2 Method for treating, managing, inhibiting, or preventing obesity Research & Business Foundation Sungkyunkwan University (KR) 2018-01-30 US claimed
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVER SITY (KR) 2017-03-30 US claimed
US-9549908-B2 Composition for inducing differentiation into beige and brown adipocytes and method of inducing the same Research & Business Foundation Sungkyunkwan University, Ltd. (KR) 2017-01-24 US claimed
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME Research & Business Foundation Sungkyunkwan University (KR) 2015-12-31 US claimed
EP-1888174-B1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER (US) 2012-02-22 EP claimed
EP-1888174-A1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS Johnson and Johnson Consumer Companies, Inc. (US) 2008-02-20 EP claimed
WO-2006127539-A1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2006-11-30 WO claimed
US-20060270614-A1 Use of chalcones for the treatment of viral disorders JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2006-11-30 US claimed
WO-1995006628-A1 TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES OR BACTERIA STATENS SERUMINSTITUT (DK) 1995-03-09 WO claimed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
WO-2006127539-A1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2006-11-30 WO disclosed
US-20060270614-A1 Use of chalcones for the treatment of viral disorders JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2006-11-30 US disclosed
EP-0370461-B1 Chalcone derivatives and process for producing the same DAINIPPON INK & CHEMICALS (JP) 1995-06-28 EP disclosed
US-5068364-A Antiulcer agents, antiallergens DAINIPPON INK AND CHEMICALS, INC. (JP) 1991-11-26 US disclosed
EP-0370461-A2 Chalcone derivatives and process for producing the same DAINIPPON INK AND CHEMICALS, INC. (JP) 1990-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 MEN1 3611/4885KMT2A 2456/4885NFKB1 1939/4885
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 MEN1 3611/4885KMT2A 2456/4885NFKB1 1939/4885
US-20060270614-A1 Use of chalcones for the treatment of viral disorders HAVCR2, HMGB3, EIF2AK2 MEN1 3326/4885KMT2A 4014/4885NFKB1 1144/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MEN1 3367/4885KMT2A 2792/4885NFKB1 1669/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885NFKB1 2437/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885NFKB1 2437/4885
US-20230099567-A1 COMPOSITION FOR TREATMENT, PREVENTION, OR AMELIORATION OF LYMPHEDEMA LIPG, LPL, LTA MEN1 4247/4885KMT2A 3466/4885NFKB1 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.